CYP3A
推薦文献

Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). “Molecular genetics of the human cytochrome P450 monooxygenase superfamily”. Xenobiotica 28 (12):  1129–65. doi:10.1080/004982598238868. PMID 9890157.
Lamba JK, Lin YS, Schuetz EG, Thummel KE (2003). “Genetic contribution to variable human CYP3A-mediated metabolism”. Adv. Drug Deliv. Rev. 54 (10):  1271–94. doi:10.1016/S0169-409X(02)00066-2. PMID 12406645.
Finta C, Zaphiropoulos PG (2001). “The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons”. Gene 260 (1–2):  13–23. doi:10.1016/S0378-1119(00)00470-4. PMID 11137287.
Gellner K, Eiselt R, Hustert E et al. (2001). “Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene”. Pharmacogenetics 11 (2):  111–21. doi:10.1097/00008571-200103000-00002. PMID 11266076.
Miyazawa M, Shindo M, Shimada T (2002). “Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes”. Xenobiotica 31 (10):  713–23. doi:10.1080/00498250110065595. PMID 11695850.
Reid JM, Kuffel MJ, Ruben SL et al. (2002). “Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans”. Clin. Cancer Res. 8 (9):  2952–62. PMID 12231541.
Martínez C, García-Martín E, Pizarro RM et al. (2002). “Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy”. Br. J. Cancer 87 (6):  681–6. doi:10.1038/sj.bjc.6600494. PMC 2364247. PMID 12237780. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364247/.
Dowling TC, Briglia AE, Fink JC et al. (2003). “Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease”. Clin. Pharmacol. Ther. 73 (5):  427–34. doi:10.1016/S0009-9236(03)00056-0. PMID 12732843.
Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD (2004). “Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes”. Drug Metab. Dispos. 32 (3):  359–63. doi:10.1124/dmd.32.3.359. PMID 14977871.
Somogyi AA, Menelaou A, Fullston SV (2005). “CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement”. Xenobiotica 34 (10):  875–87. doi:10.1080/00498250400008371. PMID 15764408.
Thompson EE, Kuttab-Boulos H, Yang L et al. (2006). “Sequence diversity and haplotype structure at the human CYP3A cluster”. Pharmacogenomics J. 6 (2):  105–14. doi:10.1038/sj.tpj.6500347. PMID 16314882.
Bochud M, Eap CB, Elston RC et al. (2006). “Association of CYP3A5 genotypes with blood pressure and renal function in African families”. J. Hypertens. 24 (5):  923–9. doi:10.1097/01.hjh.0000222763.84605.4a. PMID 16612255.
Cheung CY, Op den Buijsch RA, Wong KM et al. (2006). “Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients”. Pharmacogenomics 7 (4):  563–74. doi:10.2217/14622416.7.4.563. PMID 16753004.
Rais N, Chawla YK, Kohli KK (2007). “CYP3A phenotypes and genotypes in North Indians”. Eur. J. Clin. Pharmacol. 62 (6):  417–22. doi:10.1007/s00228-006-0105-3. PMID 16758258.
Kirby B, Kharasch ED, Thummel KT et al. (2007). “Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities”. Journal of clinical pharmacology 46 (11):  1313–9. doi:10.1177/0091270006292625. PMID 17050796.
He P, Court MH, Greenblatt DJ, von Moltke LL (2007). “Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity”. Journal of clinical pharmacology 46 (11):  1356–69. doi:10.1177/0091270006292125. PMID 17050801.
Watanabe A, Nakamura K, Okudaira N et al. (2007). “Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process”. Drug Metab. Dispos. 35 (7):  1232–8. doi:10.1124/dmd.107.015016. PMID 17392390.
Kharasch ED, Walker A, Isoherranen N et al. (2007). “Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam”. Clin. Pharmacol. Ther. 82 (4):  410–26. doi:10.1038/sj.clpt.6100237. PMID 17554244.
| 表 話  歴シトクロム酸素添加酵素: シトクロムP450  (EC 1> 14) |
| --- | --- |
CYP1:  A1  A2  B1 
CYP2:  A6  A7  A13  B6  C8  C9  C18  C19  D6  E1  F1  J2  R1  S1  U1  W1 
CYP3 (CYP3A):  A4  A5  A7  A43 
CYP4:  A11  A22  B1  F2  F3  F8  F11  F12  F22  V2  X1  Z1 
CYP5-20:  CYP5 (A1（英語版）)  CYP7 (A1（英語版）, B1)  CYP8 (A1, B1)  CYP11 (A1, B1（英語版）, B2（英語版）)  CYP17 (A1)  CYP19 (A1)  CYP20 (A1) 
CYP21-51:  CYP21 (A2)  CYP24 (A1)  CYP26 (A1, B1, C1)  CYP27 (A1, B1, C1)  CYP39 (A1)  CYP46 (A1)  CYP51 (A1（英語版）)